Sheila Ranganath,Ashok Bhandari,Nicole Avitahl-Curtis,Jaimee McMahon,Derek Wachtel,Jenny Zhang,Christopher Leitheiser,Sylvie G Bernier,Guang Liu,Tran T Tran,Herodion Celino,Jenny Tobin,Joon Jung,Hong Zhao,Katie E Glen,Chris Graul,Aliesha Griffin,Wayne C Schairer,Carolyn Higgins,Tammi L Reza,Eva Mowe,Sam Rivers,Sonya Scott,Alex Monreal,Courtney Shea,Greg Bourne,Casey Coons,Adaline Smith,Kim Tang,Ramya A Mandyam,Jaime Masferrer,David Liu,Dinesh V Patel,Angelika Fretzen,Craig A Murphy,G Todd Milne,Mark L Smythe,Kenneth E Carlson

Abstract:Interleukin-6 (IL-6) is an important member of the cytokine superfamily, exerting pleiotropic actions on many physiological processes. Over-production of IL-6 is a hallmark of immune-mediated inflammatory diseases such as Castleman's Disease (CD) and rheumatoid arthritis (RA). Antagonism of the interleukin IL-6/IL-6 receptor (IL-6R)/gp130 signaling complex continues to show promise as a therapeutic target. Monoclonal antibodies (mAbs) directed against components of this complex have been approved as therapeutics for both CD and RA. To potentially provide an additional modality to antagonize IL-6 induced pathophysiology, a peptide-based antagonist approach was undertaken. Using a combination of molecular design, phage-display, and medicinal chemistry, disulfide-rich peptides (DRPs) directed against IL-6 were developed with low nanomolar potency in inhibiting IL-6-induced pSTAT3 in U937 monocytic cells. Targeted PEGylation of IL-6 binding peptides resulted in molecules that retained their potency against IL-6 and had a prolongation of their pharmacokinetic (PK) profiles in rodents and monkeys. One such peptide, PN-2921, contained a 40 kDa polyethylene glycol (PEG) moiety and inhibited IL-6-induced pSTAT3 in U937 cells with sub-nM potency and possessed 23, 36, and 59 h PK half-life values in mice, rats, and cynomolgus monkeys, respectively. Parenteral administration of PN-2921 to mice and cynomolgus monkeys potently inhibited IL-6-induced biomarker responses, with significant reductions in the acute inflammatory phase proteins, serum amyloid A (SAA) and C-reactive protein (CRP). This potent, PEGylated IL-6 binding peptide offers a new approach to antagonize IL-6-induced signaling and associated pathophysiology.

Structure-based Design and Characterization of a Novel IL-6 Antagonist Peptide

The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling.

Structure-based Virtual Screening and Characterization of a Novel IL-6 Antagonistic Compound from Synthetic Compound Database

A Novel Hil-6 Antagonist Peptide from Computer-Aided Design Contributes to Suppression of Apoptosis in M1 Cells

The Rational Designed Antagonist Derived from the Complex Structure of Interleukin-6 and Its Receptor Affectively Blocking Interleukin-6 Might Be a Promising Treatment in Multiple Myeloma

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

Three-dimensional Structure and Function Study on the Active Region in the Extracellular Ligand-Binding Domain of Human IL-6 Receptor

Searching Interleukin 6 Antagonists by Screening Random Peptide Libraries

From Protein to a Bioactive Peptide: Potent IL‐6 Peptide Antagonist Generated by a Novel Method

De Novo Design TNF-α Antagonistic Peptide Based on the Complex Structure of TNF-α with Its Neutralizing Monoclonal Antibody Z12

Advances in Structural Base of Interaction Between Hil-6 and Its Receptor and Antagonist of Hil-6

Computational Design And Optimization Of Novel D-Peptide Tnf Alpha Inhibitors

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

Rational Design of Potent Mimic Peptide Derived from Monoclonal Antibody: Antibody Mimic Design.

Active Regions’ Setting of the Extracellular Ligandbinding Domain of Human Interleukin-6 Receptor

Structure-Based Design of Peptides against G3BP with Cytotoxicity on Tumor Cells.

A Novel BLyS Antagonist Peptide Designed Based on the 3-D Complex Structure of BCMA and BLyS

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Novel Cocrystal Structures of Peptide Antagonists Bound to the Human Melanocortin Receptor 4 Unveil Unexplored Grounds for Structure-Based Drug Design